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1The endothelin (ET) peptide family was described by Yanagisawa et al1 in 1988. They form an intricate signal-
ing system, in which 3 mature peptides (ET-1, ET-2, and ET-3) 
interact with 2 receptors (ETA and ETB).2,3 ET-1 is the main vas-
cular endothelial species and the most powerful vasoconstric-
tor. It is generated from a precursor peptide, big ET-1, through 
proteolytic cleavage by 2 ET-converting enzymes (ECE-1 and 
ECE-2, which exist in several isoforms) or other proteases.
The kidney is both a source and site of action of ET-1. 
Indeed, the renal medulla contains the highest concentration 
of immunoreactive ET-1 in the body.4 Significant amounts of 
ET-1 are detectable in most renal cell types, probably acting 
as a paracrine/autocrine regulator of renal and intrarenal blood 
flow, glomerular hemodynamics, and sodium and water trans-
port.4 ETA receptors are situated on vascular smooth muscle 
cells where they promote vasoconstriction and are thought 
to mediate many of the pathological effects of ET-1.5 In the 
kidney, ETB receptors are expressed by the vascular endo-
thelium, vascular smooth muscle, and tubular epithelial cells 
along the length of the nephron—with a particularly high den-
sity in the medullary collecting ducts.3 In vascular endothe-
lium, ETB receptor activation promotes vasodilation.2 In the 
renal tubule, preclinical data suggest that ETB receptors stimu-
late natriuresis and diuresis.3,6 To date, this action has not been 
demonstrated in man.
Understanding the effect of ET signaling on renal salt and 
water transport is important because the system makes an 
attractive target for novel therapies in disorders of fluid-elec-
trolyte homeostasis. An inability to appropriately excrete salt 
and water is a feature of many common conditions including 
chronic kidney disease (CKD), chronic liver disease, conges-
tive heart failure, and salt-sensitive hypertension. Importantly, 
salt and water retention is associated with both acute and 
chronic morbidity and mortality.7,8 ET receptor antagonists, a 
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novel class of drug currently licensed for the treatment of pul-
monary arterial hypertension and scleroderma digital ulcers,2 
are being investigated in a range of clinical conditions includ-
ing diabetic nephropathy, heart failure, and resistant hyper-
tension.2 However, salt and water retention is a common side 
effect of these agents and has led to the premature termination 
of a phase 3 clinical trial.9
It has been hypothesized that blockade of ETA receptors 
confers clinical benefit (reducing blood pressure [BP], pro-
teinuria, and renal inflammation), whereas off-target block-
ade of ETB in the renal tubule induces deleterious sodium and 
water retention.10 This hypothesis is supported by data from 
animal models, in which low doses of ET-1 promote natriure-
sis and diuresis in the absence of significant hemodynamic 
change, by stimulating ETB receptors in the renal tubule.11 
However, a direct natriuretic action of ET-1 has not yet been 
demonstrated in man. Previous studies have been confounded 
by the changes in systemic hemodynamics induced by ET 
receptor agonism and antagonism. For example, the adminis-
tration of exogenous ET-1 produces profound retention of salt 
and water accompanied by systemic and renal vasoconstric-
tion,12,13 whereas ETA blockade in CKD induces a natriuresis 
and an increase in renal blood flow.14 It is not possible to easily 
differentiate the indirect effect of any hemodynamic changes 
on renal salt and water excretion from direct effects on renal 
tubular cell function.
The aim of this study was to demonstrate a direct natri-
uretic effect of ET receptor activation in man. We adminis-
tered incremental doses of intravenous big ET-1 to healthy 
volunteers. We used big ET-1 (as opposed to ET-1), as this 
would more closely reflect normal physiology, with ET-1 
being generated only in those tissues expressing ECE. We 
hypothesized that big ET-1 would lead to a gradual increase in 
natriuresis and free water clearance (FWC) in the absence of 
significant hemodynamic changes.
Methods
Subjects
This was a 2-phase randomized, double-blind, placebo-controlled 
crossover study in 10 healthy volunteers. The study was performed 
with the approval of the local research ethics committee and the writ-
ten informed consent of each subject. The investigations conformed 
to the principles outlined in the Declaration of Helsinki.
Male and female subjects were recruited from the community be-
tween September 2006 and January 2007. To be eligible for inclusion, 
subjects had to be between 18 and 80 years of age with no medical 
history documented by their primary care physician and prescribed 
no regular medications. Other inclusion criteria were a body mass in-
dex <30 kg/m2, BP <140/90 mm Hg, normal biochemical parameters, 
and a clear urinalysis.
Study Protocol
Subjects were asked to adhere to a standardized diet (avoiding high 
salt–containing foods) for 3 days before each study day and to com-
plete two 24-hour urine collections during this time, the second 
completing on the morning of the study. These were to assess daily 
sodium intake. Subjects abstained from alcohol, caffeine, and smok-
ing for 48 hours before each study phase and, apart from a light 
breakfast on the study day, remained fasted throughout each study 
phase.
All studies were performed at the same time of day in a quiet, 
temperature-controlled room. The protocol for each study day is 
summarized in Figure S1 in the online-only Data Supplement. In 
brief, after an initial 500 mL bolus of 5% dextrose to initiate di-
uresis, a maintenance infusion (300 mL/h) continued throughout 
the study. After a 1.5-hour equilibration period, baseline measure-
ments were made over the next half hour, after which placebo or 
big ET-1 (Clinalfa) were administered. Systemic hemodynamic 
and renal responses were then followed for a period of 2.5 hours 
after the infusions were commenced. BP, cardiac output, cardiac 
index, and heart rate were recorded throughout the study by well-
validated noninvasive automated techniques15,16 every 15 minutes, 
and urine was collected every 30 minutes by spontaneous voiding 
while standing. The doses of big ET-1 used here were based on 
previous studies.17,18
Alongside systemic hemodynamic and renal responses, pulse wave 
velocity, the gold standard for measurement of arterial stiffness,19 
was measured every 30 minutes by the foot-to-foot wave velocity 
method using the SphygmoCor system (SphygmoCor Mx, AtCor 
Medical, Sydney, Australia; version 6.31), in which a high-fidelity 
micromanometer (SPC-301; Millar Instruments, TX) was used to de-
termine carotid–femoral pulse wave velocity.
Sample Collection and Analysis
Samples of venous blood were collected every 30 minutes into 
EDTA tubes (Sarstedt) for measurement of plasma ET-1 and 
osmolality and into plain tubes (Sarstedt) for serum creatinine and 
sodium. Additionally, after measuring urine volume, 20 mL aliquots 
from each voiding were collected into plain tubes for the measure-
ment of urinary creatinine, sodium, and osmolality. For urine ET-1, 
a 20 mL aliquot of urine was collected into plain tubes with 2.5 mL 
of 50% acetic acid. Blood samples were centrifuged immediately at 
2500g for 20 minutes at 4°C. All samples were stored at −80°C until 
analysis.
Plasma and urine ET-1 were determined by ELISA (R&D sys-
tems). The mean recovery of ET-1 was >95%. The intra- and interas-
say variations were 4% and 6%, respectively. The cross-reactivity of 
the assay was 23% for ET-2, 0.5% for ET-3, and there was no cross-
reactivity with big ET-1. Plasma and urine sodium concentrations 
were measured using an ion-selective electrode. Urine calcium con-
centration was measured by flame photometry (BWB Technologies 
UK). Plasma and serum osmolality was measured by freezing point 
depression using a standard osmometer. Plasma vasopressin concen-
tration was determined by ELISA (Enzo Labs). The concentration of 
total urinary nitrite and nitrate (NOx) was measured by colorimetric 
assay (780001; Cayman Chemicals, Ann Arbor, MI).
Preparation of Urinary Extracellular Vesicles
In 5 subjects, urinary extracellular vesicles were prepared by ultra-
centrifugation as previously described.20,21 Urine samples were taken 
from the collection made between 90 and 120 minutes after treatment 
with placebo or big ET-1. This was the time point at which maximal 
natriuresis and FWC were seen.
Immunoblotting
Immunoblot analyses were conducted with the experimenter blinded 
to the treatment received. The primary antibodies were rabbit anti-
AQP2 (AB3274; Millipore; 1:600), sheep anti-NKCC2 (DSTT 
Dundee; 1:10 000), and rabbit anti-NCC (AB3553; Millipore; 
1:1000); the secondary antibodies were HRP-conjugated goat anti-
rabbit Ig (sc-2301; Santa-Cruz; 1:2000) and horseradish  peroxidase–
conjugated donkey antisheep Ig (A3415; Sigma; 1:20 000). 
Immunoblot analyses were conducted with the experimenter blinded 
to the treatment received (hence, the lack of systematic lane order). 
In the densitometry analysis, band density was divided by the time 
taken to collect the urine sample used for urinary extracellular vesi-
cle preparation so that each result represents the abundance of anti-
gen excreted per unit time.
Data Analysis
Data were stored and analyzed in Graph Pad Prism, version 6.0 
(GraphPad Software, Inc, San Diego, CA). Systolic and diastolic BP 
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at each time point was calculated as the mean of 2 recordings. Mean 
arterial pressure was calculated as diastolic BP+1/3 pulse pressure. 
Bioimpedance data at each time point were calculated as the mean 
of 4 recordings, each the average of 15 consecutive heart beats. 
Data were corrected for body surface area to give cardiac index, 
for direct comparison between subjects. Systemic vascular resis-
tance index was calculated by dividing mean arterial pressure by 
cardiac index and expressed in dyne/s/m2/cm5/100. Urinary sodium 
excretion (UNaV) and ET-1 excretion were calculated as (urinary 
sodium×urinary flow rate) and (urinary ET-1×urinary flow rate), 
respectively. The fractional excretion of sodium (FeNa) and ET-1 
(FeET-1) were calculated as ([urine sodium/serum sodium×serum 
creatinine/urine creatinine]×100)% and ([urine ET-1/plasma 
ET-1×serum creatinine/urine creatinine]×100)%, respectively. 
FWC was calculated as (urine flow rate×1-urine osmolality/plasma 
osmolality).
Statistical Analysis
Baseline hemodynamic data were calculated as the mean of the 2 time 
points that immediately preceded administration of the study drug. 
For urine data, only one baseline measurement was used immediately 
before drug dosing. Hemodynamic and urine results are expressed as 
mean±SEM change from baseline for drug and placebo. Statistical 
analysis was performed on untransformed data. Responses were 
examined by repeated-measures ANOVA, and Bonferroni correction 
was used to assess significance at specific time points. Statistical sig-
nificance was taken at the 5% level.
Results
All 10 subjects fully completed the placebo and big ET-1 
phases of the study without adverse events. All subjects had 
similar baseline 24-hour urinary sodium excretion on each 
study day. Subject demographics and baseline parameters are 
shown in Table.
Plasma and Urinary ET-1
Placebo was not associated with any changes in plasma or uri-
nary ET-1 (Figure 1A through 1D). Infusion of big ET-1 led 
to a ≈1.5-fold increase in circulating ET-1 but only after the 
highest dose (Figure 1A). Plasma ET-1 gradually fell after the 
infusion of big ET-1 stopped. In parallel with this increase in 
circulating ET-1, there was a gradual ≈2.5-fold rise in urinary 
ET-1 excretion from 0.78 to 1.97 pg/min (Figure 1B). There 
were 4-fold increases in fractional excretion of ET-1 (FeET-
1) from 0.6% to 2.4% (Figure 1C) and urine ET-1/creatinine 
from 0.05 to 0.20 pg/µmol (Figure 1D).
Systemic Hemodynamics
Neither placebo nor big ET-1, at any of the 3 doses infused, 
were associated with changes in systolic or diastolic BP, sys-
temic vascular resistance index, or cardiac index (Figure 2A 
through 2D). Whereas placebo was not associated in any 
change in heart rate, infusion of big ET-1 led to an early and 
sustained fall in heart rate over the course of the study—a 
maximal fall of ≈8 bpm (Figure 3A). In keeping with the lack 
of change in BP, there was no change in pulse wave velocity 
with either placebo or big ET-1 (Figure 3B).
Renal Responses
Compared with placebo, big ET-1 infusion was associated 
with a gradual increase in UNaV (Figure 4A). This was 
maximal at 120 minutes, 30 minutes after the completion of 
the highest dose of big ET-1, and equated to ≈40 µmol/min. 
There was no change in creatinine clearance, plasma con-
centration of cystatin C, or potassium excretion with either 
placebo or big ET-1 over the time course of the study (Figure 
S2A though S2C).
Because UNaV may be affected by more subtle changes 
in intrarenal hemodynamics that may not be reflected by 
the creatinine clearance, we calculated FeNa as a measure 
of tubular sodium handling. Placebo was not associated 
with any change in FeNa over the time course of the study. 
By comparison, big ET-1 led to a marked natriuresis with a 
doubling of FeNa from 0.5% to 1.0% (Figure 4B). Placebo 
did not affect FWC. However, FWC did increase with big 
ET-1 but only after the highest dose—an increase from 4.1 
to 5.5 mL/min (Figure 4C). Interestingly, there was a posi-
tive correlation between the maximal change in FeET-1 and 
the maximal increase in FWC (r=0.83; P=0.003) such that 
those subjects showing the greatest increase in renal ET-1 
production had the greater increase in FWC (Figure S3A). 
There was a trend for this association between FeET-1 and 
FeNa (r=0.64; P=0.05; Figure S3B). The summed urinary 
excretion of nitrates and nitrites (UNOxV) increased after 
the administration of big ET-1 (Figure 4D), compatible with 
increased renal production of NO.
In a subset of subjects (n=5), we explored the molecular 
mechanisms responsible for the increased FWC induced by big 
ET-1. Big ET-1 tended to increase the plasma concentration of 
vasopressin (Figure 5A). There was also a trend to an increase 
in the abundance of aquaporin 2 (AQP2) and the bumetanide-
sensitive sodium–potassium–chloride cotransporter (NKCC2; 
Figure 5B). There was no significant difference in the abun-
dance of the thiazide-sensitive sodium-chloride cotransporter 
(Figure 5B).
Additionally, we performed a more detailed clearance 
analysis in this subset. Thus, subjects were maintained 
in hypotonic diuresis, and in this context, the fractional 
Table. Baseline Study Participant Data
Parameter n=10
Age, y 31±10 (20–49)
Sex (M/F) 8/2
BMI, kg/m2 23.7±1.9 (20.4–27.0)
SBP, mm Hg 123±9 (112–134)
DBP, mm Hg 63±9 (49–72)
Pulse, bpm 63±8 (48–72)
SVRI, dyne/s/m2/cm5 1796±355 (1420–2400)
CI, L/min/m2 4.4±0.8 (3.5–5.3)
PWV, m/s 5.4±0.9 (4.1–6.5)
Serum creatinine, mg/dL 0.92±0.11 (0.77–1.09)
24-h urine sodium, mmol/d 89±15 (56–105)
Plasma ET-1, pg/mL 1.2±0.4 (0.3–1.6)
Urine ET-1 excretion, pg/min 0.87±0.42 (0.27–1.42)
Values are given as mean of baseline pretreatment periods during the 
2 study days±SD (range). BMI indicates body mass index; CI, cardiac index; 
DBP, diastolic blood pressure; PWV, pulse wave velocity; SBP, systolic blood 
pressure; and SVRI, systemic vascular resistance index.
 by guest on M
ay 23, 2017
http://hyper.ahajournals.org/
D
ow
nloaded from
 
4  Hypertension  July 2017
delivery of sodium to the thick ascending limb (TALH) can 
be estimated by (CH2O+CNa)/100 mL glomerular filtration 
rate and the fraction of this sodium load that is reabsorbed 
in the diluting segment (approximating to the TALH) by 
(CH2O/[CH2O+CNa]×100)%.22,23 The effects of big ET-1 
on these parameters are shown in Figure S4. Big ET-1 
increased the measure of sodium reabsorption in the dilut-
ing segment but had no effect on the estimate of fractional 
sodium delivery to the TALH. Urinary calcium excretion 
was lower after big ET-1, but this did not reach significance: 
0.103±0.006 versus 0.083±0.009 mg per minute (placebo 
versus big ET-1; P=0.078).
Finally, because we were unable to discriminate between 
ETA- and ETB-mediated effects in the current study and to 
highlight the clinical importance of our findings, we analyzed 
FWC in one of our previous studies.24 Here, in both healthy 
volunteers and those with CKD, we have demonstrated that 
selective ETB receptor antagonism, but not selective ETA or 
Figure 1. Change in plasma and 
urinary endothelin-1 (ET-1). Change 
from baseline±SEM in plasma ET-1 (A), 
urinary ET-1 excretion (B), fractional 
excretion of ET-1 (FeET-1; C), and urine 
ET-1/creatinine after treatment with 
placebo (blue line) and big ET-1 (red line). 
**P<0.01, ***P<0.001, and ****P<0.0001 
for placebo vs big ET-1 (ANOVA plus 
Bonferroni correction for significance at 
specific time points).
Figure 2. Changes in systemic 
hemodynamics. Change from 
baseline±SEM in systolic BP (SBP; A), 
diastolic BP (DBP; B), systemic vascular 
resistance index (SVRI; C), and cardiac 
index (CI; D) after treatment with placebo 
(blue line) and big endothelin-1 (ET-1; red 
line).
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mixed ETA/B blockade, diminishes the capacity to clear free 
water (Figure S5).
Discussion
In this study, we have shown, for the first time in man, that 
big ET-1 stimulates renal salt excretion. This is independent 
of changes in systemic hemodynamics, arterial stiffness, 
and estimated glomerular filtration rate and so most likely 
reflects a direct action of ET-1 on the renal tubule.
Effects of Big ET-1 Are Likely Mediated Through 
Its Intrarenal Conversion to ET-1
It is unlikely that the effects seen in our study are because 
of big ET-1 directly, as radioligand-binding studies have 
established that big ET-1 does not bind to either ETA or ETB 
receptors, nor does it have any other recognized binding site.25 
Furthermore, the hemodynamic effects seen after big ET-1 
infusion in man fully depend on its conversion to ET-1.26 In 
the current study, infusion of big ET-1 led to a large rise in 
circulating ET-1 in keeping with vascular conversion as seen 
previously.27 Furthermore, given that once formed ET-1 is 
likely to bind to its receptors from which it dissociates slowly, 
plasma ET-1 concentration is probably an underestimate of its 
production. The exact site of the vascular conversion of big 
ET-1 to ET-1 remains unclear but is unlikely to be in whole 
human blood28 or in the vascular endothelium.29 The extracel-
lular surface of the smooth muscle cell has been identified as 
a plausible location for this conversion.30
It seems likely that the increase in urinary ET-1 excre-
tion was because of the intrarenal conversion of big ET-1 
to ET-1 for 2 reasons. First, this can be predicted from the 
existing literature. Isotope studies in animals31 and clear-
ance studies in man32 have shown that ET-1 in the urine is 
likely to be generated within the kidney (rather than being 
filtered or secreted into the urinary space from the plasma). 
ECE isoforms are expressed in the renal microvascular and 
the tubular epithelium.3,33 Second, urine ET-1 excretion 
(measured as net excretion or as fractional excretion of the 
filtered load) increased before any detectable rise in circu-
lating ET-1 (ie, when big ET-1 was infused at lower doses). 
This short time course also suggests that ET-1 was likely 
to be generated from the intrarenal conversion of big ET-1 
to mature peptide rather than de novo generation. Our data 
are consistent with a previous smaller study in healthy man 
that suggested an increase in renal ET-1 production after big 
ET-1 infusion.34
Lack of Significant Hemodynamic Effect
Importantly, big ET-1 did not affect systemic hemodynamics 
at any of the doses given. There was no detectable change in 
systolic or diastolic BP. There was no evidence of systemic 
vasoconstriction, given the lack of change in systemic vascu-
lar resistance or cardiac output. We did observe a fall in heart 
rate, the magnitude of which was similar to that seen in ear-
lier studies where big ET-1 has been infused in human sub-
jects.18,34 This is unlikely to be a baroreceptor reflex because 
BP remained constant. Thus, this negative chronotropy likely 
reflects a direct effect of ET-1 on the heart, an effect pre-
viously reported in preclinical studies.35 We observed no 
change in creatinine clearance or plasma cystatin C, both 
estimates of glomerular filtration rate, over the time course of 
the study, suggesting that there was no significant change in 
renal hemodynamics at the doses of big ET-1 used. For com-
parison, a previous study that infused big ET-1 into healthy 
humans and found significant changes in systemic and renal 
hemodynamics used a dose that was ≈2-fold greater than the 
highest dose used here (≈600 pmol given intravenously over 
20 minutes compared with 300 pmol given over 30 minutes 
here).34 Others have administered a similar dose of big ET-1 
to that used in the current study to patients with end-stage 
renal disease, and this did indeed increase BP (and reduce 
splanchnic blood flow), but this likely reflects the fact that 
patients with renal disease have an activated ET system and 
are more sensitive to its effects.4,24
However, we cannot exclude regional changes in renal 
cortical or medullary blood flow (which are not readily 
assessable in man). Such changes are recognized after infu-
sion of ET-1 in animals36,37 and may affect tubular handling 
Figure 3. Changes in heart rate and arterial stiffness. Change 
from baseline±SEM in heart rate (A) and pulse wave velocity 
(PWV; B) after treatment with placebo (blue line) and big 
endothelin-1 (ET-1; red line). *P<0.05 for placebo vs big ET-1 
(ANOVA plus Bonferroni correction for significance at specific 
time points).
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of salt and water. Indeed, we found that the excretion of NO 
metabolites was increased after big ET-1. In rodent mod-
els, ET-1 has been shown to increase renal NO production 
(through its action on ETB receptors in the collecting duct),38 
which elicits diuresis and natriuresis.39,40 These effects of NO 
may be mediated, in part, by changes in regional blood flow 
within the kidney.41
Natriuretic Effect of Big ET-1
As hypothesized, big ET-1 infusion led to a significant natriure-
sis as shown by the increases in both UNaV and FeNa of ≈40% 
from baseline. If this was maintained over a 24-hour period, it 
would amount to ≈60 mmol of sodium excreted in the urine 
and is broadly equivalent to the natriuresis elicited by a single 
25 mg dose of spironolactone.42 Our subjects were healthy and 
relatively sodium restricted (with a sodium intake of ≈90 mmol 
Na or ≈5 g NaCl per day, ≈50% of that contained in a standard 
Western diet); it is unclear whether the natriuretic effect of ET-1 
would be different on a high-salt diet or in patient populations in 
which there is activation of the renin–angiotensin–aldosterone 
system, such as in congestive heart failure, CKD, or liver cir-
rhosis. This would be of particular interest, because maximizing 
renal salt and water excretion is an important focus of clinical 
management in these patient groups.
In animal models, ET-1 inhibits sodium reabsorption 
along the length of the renal tubule.3,43 Our data strongly sug-
gest that the natriuretic effect of big ET-1 is not localized to 
the TALH. Indeed, clearance data (CH2O/[CH2O+CNa]) point 
to increased sodium reabsorption in this segment, consistent 
with the ≈35% increase in FWC and the trend to reduced uri-
nary calcium excretion.22,23
These functional data are supported by our molecular data 
showing that the abundance of NKCC2 on urinary extracellular 
vesicles was increased by big ET-1 (and furthermore that the 
observed increase in AQP2 expression occurred in a direction 
that would oppose free water clearance). Enhanced transport in 
the TALH sits at odds with the established literature; ET-1 has 
been consistently shown to inhibit NKCC2 activity (via ETB 
receptors acting through NO-dependent and NO-independent 
pathways).3,44 This apparent conflict may be explained by our 
finding that big ET-1 increased the concentration of circulating 
vasopressin (another established ET-1 effect).45 Vasopressin 
increases the renal expression of both NKCC2 and AQP2, and 
we speculate that this indirect effect of big ET-1 over-rides any 
direct effect of ET receptor activation in the TALH. As over-
all FeNa increased, if sodium reabsorption was no different in 
the proximal tubule or distal convoluted tubule and stimulated 
in the TALH, then sodium reabsorption must have been sup-
pressed elsewhere in the nephron (ie, connecting tubule or 
collecting ducts). We attempted to assess the abundance of 
ENaC subunits in urinary vesicles but were unable to generate 
detectable bands on Western blot (presumably because of the 
low abundance of antigen in urine samples that were rendered 
dilute by the water-loading protocol).
ETB Receptors Are Likely to Mediate Aquaresis  
and Natriuresis
Preclinical studies have demonstrated that big ET-146 and ET-13 
promote natriuresis and diuresis through an ETB receptor-
mediated, NO-dependent, mechanism. In the present study, 
we did not attempt to directly differentiate between ETA- and 
ETB-mediated effects. However, in a separate cohort of healthy 
volunteers and patients with CKD, we have demonstrated that 
ETB blockade diminishes the capacity to clear free water. Thus, 
the results of our present study are consistent with big ET-1 
acting (after conversion to ET-1) on ETB receptors to increase 
free water clearance. Furthermore, our finding of increased 
excretion of NO metabolites supports an ETB-mediated effect.
Figure 4. Changes in renal responses. 
Change from baseline±SEM in urinary 
sodium clearance (UNaV; A), fractional 
excretion of sodium (FeNa; B), free water 
clearance (FWC; C), and urinary excretion 
of NO metabolites (UNOxV; D) after 
treatment with placebo (blue line) and 
big endothelin-1 (ET-1; red line). *P<0.05, 
**P<0.01, and ****P<0.0001 for placebo 
vs big ET-1 (ANOVA plus Bonferroni 
correction for significance at specific time 
points).
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Perspectives
In healthy volunteers, subpressor doses of big ET-1 induced 
natriuresis and aquaresis, effects likely mediated through 
renal tubular ETB receptors (after intrarenal conversion 
to mature ET-1). Our clearance and molecular data sug-
gest that sodium reabsorption was stimulated by ET-1 in 
the TALH but inhibited in distal nephron segments. Taken 
together with the preclinical literature, our data support the 
potential use of highly selective ETA receptor antagonists 
in clinical conditions associated with salt and water reten-
tion. In line with this, preclinical studies in congestive heart 
failure supported a selective ETA-blocking approach.5 Long-
term clinical studies, however, have been disappointing. 
However, all have used nonselective antagonists or mod-
estly ETA-selective antagonists at doses that probably block 
the ETB receptor. Therefore, it may well be that a truly ETA-
selective approach has not yet been studied. Fortunately, 
studies using a selective approach in CKD have been 
encouraging,14,47 and the outcomes of a large phase 3 study 
(SONAR [Study of Diabetic Nephropathy with Atrasentan]) 
are eagerly awaited.48 As an alternative to selective ET 
receptor blockade, our data provide a rationale for testing 
potassium-sparing diuretics (rather than loop diuretics) in 
an attempt to ameliorate the fluid retention associated with 
ET receptor antagonists. Although this strategy has not, to 
our knowledge, been tested prospectively, a post hoc analy-
sis of the ARIES trial (Ambrisentan in Pulmonary Arterial 
Hypertension, Randomized, Double-Blind, Placebo-
Controlled, Multicenter, Efficacy Studies) found that copre-
scription of spironolactone with ambrisentan was associated 
with better outcomes in pulmonary arterial hypertension.49
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Figure 5. Molecular mechanisms 
regulating free water clearance. 
Change from baseline±SEM in plasma 
concentration of vasopressin (A). Effect of 
big endothelin-1 (ET-1) on the abundance 
of AQP2, NKCC2, and sodium-
chloride cotransporter (NCC) in urinary 
extracellular vesicle (uEVs), assessed 
by immunoblot (B). For AQP2, bands 
were detected at 28–35 and 40–55 kDa, 
corresponding to the nonglycosylated 
and glycosylated forms, respectively. 
Urine samples from subject number 5 
were not available in sufficient quantity to 
prepare uEVs for the NCC blot.
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What Is New?
•	This is the first study to explore the effects of big endothelin-1 (ET-1) on 
renal sodium and water handling in man.
•	Our study protocol allowed us to determine the effects of big ET-1 on the 
kidney without significant hemodynamic perturbation.
What Is Relevant?
•	Big ET-1 infusion elicited a clinically significant natriuresis and diuresis.
•	Renal clearance data and a molecular analysis of sodium transporter 
expression in urinary extracellular vesicles suggest that big ET-1 inhibits 
sodium reabsorption through ENaC in the collecting ducts.
•	Endothelin receptor antagonists have been associated with edema and 
heart failure in clinical trials. Our results suggest this adverse effect is a 
consequence of stimulated sodium reabsorption in the collecting ducts.
Summary
In healthy, infusion of big ET-1 elicited a natriuresis (via inhibition 
of sodium reabsorption in the renal collecting ducts). Blockade of 
this pathway may account for the edema and heart failure observed 
with the clinical use of endothelin receptor antagonists. Our data 
support the use of potassium-sparing diuretics as a therapeutic 
strategy to ameliorate fluid retention associated with these agents.
Novelty and Significance
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Supplementary Methods 
Standardized salt diet 
We provided study participants with information in order to standardize their salt intake 
(Supplementary table S1). Unpublished data from previous studies in our department suggest that 
adherence to this modified diet allows for a 24h urinary sodium excretion of ~100mmol. This is 
equivalent to ~6g of salt intake per day.    
 
‘It is important for this study for you to have a uniform intake of salt in your diet. This is to 
standardize the effect of salt on your kidney’s response to the drugs we are using. We would like you, 
therefore, to adhere as closely as possible to the following guidelines for the 3 days before your study 
day. Salt can be used in cooking but avoid adding it afterwards. A small amount of stock cube or 
Bisto may be used for seasoning stews, soups etc. but make sure that it is not too salty. Salt 
substitutes e.g. ‘Lo Salt’ or ‘Pan Salt’ should not be used.’ 
 
Preparation of urinary extracellular vesicles (uEVs) 
After thawing overnight at 4°C, urine was vortexed vigorously and 4ml taken, to which protease and 
phosphatase inhibitors were added (final concentration in mM: NaN3 3.3, PMSF 0.5, leupeptin 0.002, 
EDTA 2, NaF 50, sodium -glycerophosphate 25, Na4P2O7 5, Na3VO4 10). Samples were centrifuged 
at 15,000g for 15 mins at 4°C and the supernatant (S1) transferred to an ultracentrifuge tube. The 
pellet was disrupted by re-suspending in 222 mg/ml DTT in isolation solution and incubating at 37°C 
for 5 mins with frequent vortexing. These samples were centrifuged at 15,000g for 15 mins at 4°C 
and the supernatant (S2) combined with S1. The pooled supernatants were centrifuged at ~100,000g 
(54,000rpm in an MLA-80 rotor on a Beckman OptimaTM MAX-E ultracentrifuge) for 60 mins at 
4°C. The pellet was resuspended in 20 microL resuspension buffer (in mM: TEA 10, sucrose 250, pH 
7.6 with protease and phosphatase inhibitors as above). These were solubilized by the addition of 15 
microL LDS sample buffer and heated to 70°C for 15 mins before being used for SDS-PAGE. 
 
Immunoblotting 
SDS-PAGE was performed on a 12% Tris-HEPES gel (PreciseTM, ThermoScientific). Gels were 
stained with Coomassie blue or transferred to a PVDF membrane (Hybond-P, Amersham) for 
immunoblotting. 15l of each sample was loaded, in order to provide bands whose density was 
within the linear range of detection. Antibody details are given in the main methods. Peroxidase 
activity was revealed using SuperSignal West Pico Chemiluminescent Substrate to expose 
photographic film. To measure band density, films were photographed using a digital SLR camera 
(Nikon D40) with the exposure set to maximize dynamic range without significant pixel saturation. 
Images were analyzed as 8-bit.tiffs in ImageJ (version 1.43u). A rectangular region of interest (ROI) 
was drawn to encompass the entire vertical range of each lane and the area under this curve was 
taken as a measure of the band density. No background subtraction step was applied.  
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Supplementary table S1: Dietary salt advice 
 
Very salty foods - please avoid Alternatives 
Cheese e.g. cheddar, Edam Cottage cheese 
Tinned meats e.g. corned beef, spam, luncheon 
meat, chicken roll, bacon, ham, gammon, 
haggis, black pudding, white pudding, 
sausages 
Fresh or frozen beef, lamb or pork, mince, stew, 
chops, liver, poultry, e.g. chicken, turkey 
Tinned and smoked fish e.g. smoked haddock, 
kippers, sardines, pilchards, tuna, smoked 
salmon, shellfish 
Fresh or frozen fish e.g. haddock, whiting, sole, 
plaice, cod, herring 
Tinned and packet soups Homemade soup using a little salt or a small 
piece of stock cube. Avoid ham bones for 
making stock- other bones are suitable e.g. 
chicken 
Tinned vegetables Fresh or frozen vegetables. Tinned vegetables 
without salt e.g. Del Monte 
Bovril, marmite, soy sauce, monosodium 
glutamate, salted nuts and crisps, sauce for 
chips, liver salts, sodium bicarbonate 
Pepper, mustard, vinegar, herbs, spices 
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Supplementary figure S1: Study design 
BP: blood pressure; PWV: pulse wave velocity. 
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Supplementary figure S2: Creatinine clearance, cystatin C & urinary potassium excretion 
Creatinine clearance (A), plasma concentration of cystatin C (B) and urinary potassium excretion 
(C); mean ± SEM following treatment with placebo (blue line) and big ET-1 (red line). 
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Supplementary figure S3: Correlations of FeET-1 
Correlation between the maximal change in fractional excretion of ET-1 (FeET-1) and the maximal 
change in free water clearance (FWC) (A) and fractional excretion in sodium (FeNa) (B). 
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Supplementary figure S4: Effect of big ET-1 on clearance parameters during hypotonic diuresis. 
Effect of big ET-1 on [(CH2O + CNa)/GFR], an estimate of sodium delivery to the TALH and on 
[CH2O/(CH20+CNa)], an estimate of sodium reabsorption in the TALH.  
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Supplementary figure S5: Effect of selective & mixed ET receptor antagonism on free water 
clearance. 
These previously unpublished data were obtained from a double-blind cross-over study of selective 
ET-1 receptor antagonism in health and chronic kidney disease (n = 8 for both). During water 
diuresis, subjects received BQ123 (an ETA antagonist) or BQ788 (ETB antagonist) alone or in 
combination. Selective ETB antagonism induced retention of free water in both cohorts. 
*p <0.05, **p 
<0.01 and ****p <0.0001 for BQ788 alone vs. BQ123 and vs. BQ123/788. +p <0.05 and ++p <0.01 for 
BQ788 alone vs. placebo. 
 
